Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9190 in healthy adults
NCT06932315Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-9190 in Spasticity, sponsored by Hengrui. Primary endpoint: Adverse events at 7 days. Started Apr 2025; status: completed.
02
Drugs
HRS-9190
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT06932315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932315.